• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Effect of estrogen treatment and vitamin D status on differing bioavailabilities of calcium carbonate and calcium citrate.
【24h】

Effect of estrogen treatment and vitamin D status on differing bioavailabilities of calcium carbonate and calcium citrate.

机译：雌激素治疗和维生素D状态对碳酸钙和柠檬酸钙不同生物利用度的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The authors hypothesized that estrogen treatment or vitamin D status may affect the bioavailability of two common calcium supplements differently. Using data derived from a recent trial in 25 postmenopausal women, the authors found that deltaAUC of serum calcium after subtraction of placebo was significantly higher after calcium citrate (median, 0.85; 25th to 75th percentile, 0.70 to 3.15) than after calcium carbonate (0.25; -0.58 to 1.00) in non-estrogen-treated patients. There was no difference in the bioavailability of calcium between the two calcium formulations in estrogen-treated patients. Bioavailability was also significantly higher with the citrate salt for the subgroups with lower serum 25-hydroxyvitamin D and higher serum 1,25-dihydroxyvitamin D concentrations. In summary, bioavailability of calcium from the calcium carbonate product was more dependent on estrogen treatment and vitamin D status than that of calcium citrate. This may explain the variable results of reported calcium supplementation studies.
机译：作者假设雌激素治疗或维生素D状态可能对两种常见钙补充剂的生物利用度产生不同的影响。作者使用最近对25名绝经后妇女进行的一项试验得出的数据，作者发现，扣除安慰剂后，血清钙的deltaAUC明显高于碳酸钙（0.25）后的柠檬酸钙（中位数，0.85; 25至75％，0.70至3.15）。 ; -0.58至1.00）在未接受雌激素治疗的患者中。在雌激素治疗的患者中，两种钙制剂之间的钙生物利用度没有差异。对于血清25-羟基维生素D较低和血清1,25-二羟基维生素D较高的亚组，柠檬酸盐的生物利用度也显着较高。总之，与柠檬酸钙相比，碳酸钙产品中钙的生物利用度更依赖于雌激素治疗和维生素D状态。这可能解释了钙补充研究的不同结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号